Brief: Pieris Pharmaceuticals Astrazeneca Communicated To Company Its Decision To Discontinue And Cease Dosing In Ongoing Clinical Studies Of Elarekibep

Palvella Therapeutics

21/06/2023 12:17

June 21 (Reuters) - AstraZeneca PLC  AZN.L :
    * PIERIS PHARMACEUTICALS : ASTRAZENECA COMMUNICATED TO
COMPANY ITS
DECISION TO DISCONTINUE AND CEASE DOSING IN ONGOING CLINICAL
STUDIES OF ELAREKIBEP
    * PIERIS PHARMACEUTICALS : DECISION BASED ON LUNG FINDINGS
FROM
NON-CLINICAL 13-WEEK GLP TOXICOLOGY STUDY WITH DRY POWDER
INHALER-FORMULATED ELAREKIBEP
    * PIERIS PHARMACEUTICALS INC: ASTRAZENECA'S DECISION WAS
MADE
INDEPENDENT OF ANY DATA FROM PHASE 2A STUDY - SEC FILING
    * PIERIS PHARMACEUTICALS INC: COMPANY WILL EXPEDITE A REVIEW
OF
IMPLICATIONS OF DATA AND ASTRAZENECA'S DECISION
    * PIERIS: ASTRAZENECA CONCLUDED THERE WERE NO CLINICAL
OBSERVATIONS ACROSS ANY OF DOSES BUT THAT THERE WERE RESPIRATORY
TRACT PATHOLOGY FINDINGS

Source text for Eikon:  ID: 
Further company coverage:  AZN.L 

 ((reuters.briefs@thomsonreuters.com;))